The Goldilocks problem in oncology RWD: choosing the data that’s 'just right'

Marketing information 
Oncology real-world data is being increasingly utilized to offer greater insights into how treatments perform in broader patient populations over longer periods of time. This comprehensive view of patient journeys leads to advanced personalized treatment strategies, improved patient care and more informed cancer research. Yet incorporating oncology RWD into clinical development programs and accessing the relevant datasets is challenging. By understanding the complexity and nuances of oncology RWD, including its collection and analysis, and determining which data is 'just right', researchers can make more informed decisions throughout the entirety of clinical development and oncology practice.

Chaired by Wendy Turenne (Senior VP of Real-World Data and Delivery Operations, Aetion), the expert panel will include industry-leading experts from oncology RWD providers partnering with Aetion in the Accelerated Access: Oncology solution. They will discuss how to overcome challenges associated with oncology RWD to drive better decision-making and improve patient outcomes, enabling you to determine what 'just right' means for you!

Panelists:
  • Andrew Belli, Vice President, Research, COTA
  • Mark Shapiro, Chief Operating Officer, xCures

About Accelerated Access: Oncology
With the ability of RWE to inform all phases of the product lifecycle, the availability of oncology RWD is rapidly expanding. While many RWD vendors offer solutions, selecting the right oncology data for your research question can be difficult. 

Accelerated Access: Oncology simplifies the data selection process by providing rapid access to several oncology datasets from three industry-leading providers, spanning 18 common tumor types, on the scientifically validated platform, Aetion® Substantiate, and increases the return on your oncology data investments by utilizing Aetion’s oncology expertise and technology to generate RWE.

Your details

Terms & Conditions

Subscribing to

Confirm sign-up

What you will learn:

  • Understand the intricacies of oncology care and the measurable outcomes captured through RWD
  • Dive deep into the most critical elements for oncology, such as biomarkers, progression and mortality
  • Discuss strategies for extracting insights from unstructured EMR data, such as clinical genomic data and medical images
Chair:

Wendy Turenne 
Senior VP of Real-World Data, Aetion

Wendy Turenne is a healthcare analytics specialist with over 20 years of experience building bridges between data, analytics and business strategy. As Senior VP of Real-World Data, Wendy leads data strategy, partnerships and integration, as well as operational performance for Aetion.  Previous to joining Aetion, Wendy partnered with biopharmaceutical companies of all sizes on RWE and HEOR collaborations with Cardinal Health and DaVita. Prior to that, she held analytics and leadership positions across multiple settings: government, population health, hospital, payer, and provider organizations. She holds a BS from the University of Virginia and a MS in Biostatistics from the University of North Carolina, Chapel Hill.

Panelists:
Andrew Belli
Vice President, Research, COTA

Andrew (Drew) Belli is the Vice President of Research at COTA, an oncology real-world data, analytics, and technology company. In this role, he oversees the execution of COTA’s research initiatives with healthcare providers, life sciences companies, and non-profit/regulatory partners. Prior to joining COTA, Drew worked in academic research and healthcare consulting and earned his MPH from Johns Hopkins Bloomberg School of Public Health.

Mark Shapiro
Chief Operating Officer, xCures

Mark Shapiro is the Chief Operating Officer at xCures and principal investigator for XCELSIOR, a patient-powered real-world data and outcomes registry in cancer. For two decades Mark has been driving growth and innovation programs in clinical research. Prior to joining xCures, Mr Shapiro was Senior Vice President of Operations at a global CRO, where he was responsible for a team of about 500 drug development professionals in 30 countries, and a portfolio of more than 100 active clinical trials.

Share this webinar